Keybanc Maintains Overweight on ResMed, Raises Price Target to $251
Portfolio Pulse from Benzinga Newsdesk
Keybanc analyst Brett Fishbin maintains an Overweight rating on ResMed (NYSE:RMD) and raises the price target from $238 to $251.
August 02, 2024 | 4:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Keybanc analyst Brett Fishbin maintains an Overweight rating on ResMed and raises the price target from $238 to $251, indicating a positive outlook for the stock.
The raised price target and maintained Overweight rating from a reputable analyst suggest a positive short-term impact on ResMed's stock price. Investors are likely to view this as a strong endorsement of the company's prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100